1. Home
  2. MIRM vs VTMX Comparison

MIRM vs VTMX Comparison

Compare MIRM & VTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIRM
  • VTMX
  • Stock Information
  • Founded
  • MIRM 2018
  • VTMX 1998
  • Country
  • MIRM United States
  • VTMX Mexico
  • Employees
  • MIRM N/A
  • VTMX N/A
  • Industry
  • MIRM Biotechnology: Pharmaceutical Preparations
  • VTMX
  • Sector
  • MIRM Health Care
  • VTMX
  • Exchange
  • MIRM Nasdaq
  • VTMX Nasdaq
  • Market Cap
  • MIRM 2.2B
  • VTMX 2.3B
  • IPO Year
  • MIRM 2019
  • VTMX 2023
  • Fundamental
  • Price
  • MIRM $50.34
  • VTMX $26.78
  • Analyst Decision
  • MIRM Strong Buy
  • VTMX Sell
  • Analyst Count
  • MIRM 12
  • VTMX 2
  • Target Price
  • MIRM $63.17
  • VTMX $27.50
  • AVG Volume (30 Days)
  • MIRM 397.8K
  • VTMX 155.0K
  • Earning Date
  • MIRM 08-06-2025
  • VTMX 07-24-2025
  • Dividend Yield
  • MIRM N/A
  • VTMX 2.62%
  • EPS Growth
  • MIRM N/A
  • VTMX N/A
  • EPS
  • MIRM N/A
  • VTMX 0.13
  • Revenue
  • MIRM $379,251,000.00
  • VTMX $258,927,122.00
  • Revenue This Year
  • MIRM $35.83
  • VTMX $17.35
  • Revenue Next Year
  • MIRM $16.83
  • VTMX $11.82
  • P/E Ratio
  • MIRM N/A
  • VTMX $20.41
  • Revenue Growth
  • MIRM 69.31
  • VTMX 15.06
  • 52 Week Low
  • MIRM $28.56
  • VTMX $21.30
  • 52 Week High
  • MIRM $54.23
  • VTMX $32.84
  • Technical
  • Relative Strength Index (RSI)
  • MIRM 69.78
  • VTMX 33.18
  • Support Level
  • MIRM $48.78
  • VTMX $27.54
  • Resistance Level
  • MIRM $50.05
  • VTMX $27.82
  • Average True Range (ATR)
  • MIRM 1.64
  • VTMX 0.51
  • MACD
  • MIRM 0.39
  • VTMX -0.30
  • Stochastic Oscillator
  • MIRM 87.92
  • VTMX 0.56

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About VTMX Corporacion Inmobiliaria Vesta S.A.B de C.V. each representing ten (10)

Corporacion Inmobiliaria Vesta SAB de CV is an internally managed real estate company that owns, manages, develops, and leases industrial properties in Mexico. The Company's primary business is the acquisition, development, and management of industrial and distribution center real estate. The company designs and constructs park-to-suit projects across various industries; undertakes build-to-suit projects; and provides site selection, design and engineering, and sale and leaseback services. The primary source of revenue is the rental income received from customers under operating leases. It serves aerospace, automotive, food and beverage, logistics, medical devices, plastics, and other industries.

Share on Social Networks: